De Lorenzo Giuditta, Tandavanitj Rapeepat, Preciado-Llanes Lorena, Sanchez-Velazquez Ricardo, Prado Rocha Raissa, Kim Young Chan, Reyes-Sandoval Arturo, Patel Arvind H
MRC-University of Glasgow Centre for Virus Research, Glasgow, United Kingdom.
Research and Technology Institute, Area Science Park, Trieste, Italy.
Front Immunol. 2025 Apr 25;16:1578427. doi: 10.3389/fimmu.2025.1578427. eCollection 2025.
Zika virus (ZIKV) remained poorly studied until an outbreak in 2015 linked the virus to severe neurological disorders and congenital malformations. Currently, there are no antiviral drugs or vaccines available. We have previously demonstrated that a simian adenovirus vector vaccine (ChAdOx1 prMEΔTM) and a virus-like particle-based vaccine bearing E proteins locked in covalent dimers (VLP-cvD) are effective against ZIKV infection in animal challenge models. In this study, we further explored the efficacy of these vaccines, either individually or in combination, using a heterologous prime and boost vaccination strategy in mouse challenge models. Although the individual vaccines provided good protection levels, the heterologous prime-boost vaccination regimen (ChAdOx1 prMEΔTM followed by VLP-cvD) offered the most effective protection. This regimen elicited a strong cellular response and high levels of neutralising antibodies, which were attributed to ChAdOx1 prMEΔTM and VLP-cvD, respectively. Our findings support the use of combined vaccine technologies and offer valuable insights into the multifactorial protection achievable through heterologous vaccination. These results have important implications for the development of effective vaccination strategies against ZIKV and other emerging viruses.
直到2015年爆发疫情，将寨卡病毒（ZIKV）与严重的神经疾病和先天性畸形联系起来，人们对该病毒的研究一直很少。目前，尚无可用的抗病毒药物或疫苗。我们之前已经证明，一种猿猴腺病毒载体疫苗（ChAdOx1 prMEΔTM）和一种基于病毒样颗粒的疫苗（其E蛋白以共价二聚体形式锁定，即VLP-cvD）在动物攻毒模型中对ZIKV感染有效。在本研究中，我们在小鼠攻毒模型中采用异源初免-加强免疫策略，进一步探究了这些疫苗单独使用或联合使用时的效果。尽管单独的疫苗提供了良好的保护水平，但异源初免-加强免疫方案（先接种ChAdOx1 prMEΔTM，随后接种VLP-cvD）提供了最有效的保护。该方案引发了强烈的细胞反应和高水平的中和抗体，分别归因于ChAdOx1 prMEΔTM和VLP-cvD。我们的研究结果支持联合疫苗技术的使用，并为通过异源接种可实现的多因素保护提供了有价值的见解。这些结果对开发针对ZIKV和其他新兴病毒的有效疫苗策略具有重要意义。
